Our research has led to breakthroughs in treatment and continues to improve care that brings hope to the entire Parkinson's community. Since 1957, the Foundation has invested more than $330 million in Parkinson’s disease (PD) research and clinical care.
In the last 60 years we have actively worked to defeat Parkinson’s, supporting research initiatives that have revolutionized the field. The Parkinson’s Foundation has directly funded the studies that have led to:
- The development of the first standard tool to measure Parkinson’s progression
- The first blind clinical trial of levodopa
- Established what is now the largest movement disorders training program in the world
- The discovery of the first PD-associated gene called alpha-synuclein, which has proven critical to new treatments under development.
Since research plays a vital role in helping us better understand Parkinson’s, the Parkinson’s Foundation funds and supports multiple types of research. In addition to hosting the largest clinical study in Parkinson’s and funding numerous clinical and observational studies, the Foundation has developed the Scientific Advisory Board to identify the most pressing PD issues that need the attention of the research field.
We actively work to better understand Parkinson’s from the perspective of everyone in our PD community, including people living with PD, caregivers, researchers, healthcare professionals and research advocates.